Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 414

  • Showing results for matera m. Search instead for Materna M (2 items)
1.

Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review.

Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P.

Expert Rev Respir Med. 2020 Mar 13. doi: 10.1080/17476348.2020.1743180. [Epub ahead of print]

PMID:
32168461
2.

The effect of doxofylline in asthma and COPD.

Cazzola M, Matera MG.

Respir Med. 2020 Apr;164:105904. doi: 10.1016/j.rmed.2020.105904. Epub 2020 Feb 19. Review.

PMID:
32094104
3.

TSLP Inhibitors for Asthma: Current Status and Future Prospects.

Matera MG, Rogliani P, Calzetta L, Cazzola M.

Drugs. 2020 Apr;80(5):449-458. doi: 10.1007/s40265-020-01273-4.

PMID:
32078149
4.

α1-Antitrypsin deficiency and chronic respiratory disorders.

Cazzola M, Stolz D, Rogliani P, Matera MG.

Eur Respir Rev. 2020 Feb 12;29(155). pii: 190073. doi: 10.1183/16000617.0073-2019. Print 2020 Mar 31. Review.

5.

Severe Asthma and Biological Therapy: When, Which, and for Whom.

Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M.

Pulm Ther. 2019 Dec 26. doi: 10.1007/s41030-019-00109-1. [Epub ahead of print] Review.

PMID:
32048241
6.

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Pulm Ther. 2019 Dec;5(2):117-126. doi: 10.1007/s41030-019-00102-8. Epub 2019 Nov 2. Review.

7.

A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma.

Matera MG, Rinaldi B, Berardo C, Rinaldi M, Cazzola M.

Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):143-148. doi: 10.1080/17425255.2020.1716730. Epub 2020 Jan 30. Review.

PMID:
31958237
8.

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.

Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P.

Pulm Pharmacol Ther. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883. Epub 2019 Dec 26.

9.

The future of bronchodilation: looking for new classes of bronchodilators.

Cazzola M, Rogliani P, Matera MG.

Eur Respir Rev. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review.

10.

Pharmacology and Therapeutics of Bronchodilators Revisited.

Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M.

Pharmacol Rev. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.

PMID:
31848208
11.

Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.

Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L.

Br J Pharmacol. 2020 Mar;177(5):1150-1163. doi: 10.1111/bph.14909. Epub 2020 Jan 29.

PMID:
31660611
12.

Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.

Calzetta L, Matera MG, Cazzola M, Rogliani P.

Adv Ther. 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.

13.

Isolated airways in equine respiratory pharmacology: They never lie.

Calzetta L, Pistocchini E, Ritondo BL, Roncada P, Cito G, Britti D, Matera MG.

Pulm Pharmacol Ther. 2019 Dec;59:101849. doi: 10.1016/j.pupt.2019.101849. Epub 2019 Sep 22.

PMID:
31553927
14.

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.

Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L.

Pulm Pharmacol Ther. 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841. Epub 2019 Sep 11.

PMID:
31520718
15.

Pharmacological treatment and current controversies in COPD.

Cazzola M, Rogliani P, Stolz D, Matera MG.

F1000Res. 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019. Review.

16.

Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Cazzola M, Calzetta L, Rogliani P, Matera MG.

Expert Opin Investig Drugs. 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990. Epub 2019 Sep 1. Review.

PMID:
31474120
17.

Ultra-LABAs for the treatment of asthma.

Cazzola M, Rogliani P, Matera MG.

Respir Med. 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005. Epub 2019 Aug 12. Review.

PMID:
31425937
18.

A potential role of triple therapy for asthma patients.

Cazzola M, Puxeddu E, Matera MG, Rogliani P.

Expert Rev Respir Med. 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408. Epub 2019 Sep 1.

PMID:
31422716
19.

Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.

Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG.

Multidiscip Respir Med. 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019.

20.

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment.

Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M.

Pulm Pharmacol Ther. 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828. Epub 2019 Jul 23. Review.

PMID:
31349002

Supplemental Content

Loading ...
Support Center